REGENXBIO reports Phase III RGX-202 Duchenne trial data and Q1 2026 earnings
Filed May 14, 2026 · Period ending May 14, 2026 · ~1 min read
3 material changes detected in this filing.
Create a free account to read the full summary — it takes 30 seconds.
Partner
Trade RGNX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 4, 2026 4:21 PM